Literature DB >> 32878707

MSCs attenuate hypoxia induced pulmonary hypertension by activating P53 and NF-kB signaling pathway through TNFα secretion.

Jinjun Liu1, Jing Li2, Caixia Xie1, Ling Xuan1, Bi Tang3.   

Abstract

Hypoxia could cause vascular smooth muscle hypertrophy, leading to high pulmonary circulation resistance, pulmonary artery (PA) pressure, even pulmonary arterial hypertension (PAH). Recent studies have demonstrated the ability of mesenchymal stem cell (MSC) to ameliorate PAH but the mechanism was controversial. In this study, we revealed that the growth rate of pulmonary artery smooth muscle cells (PASMCs) treated with hypoxia was significantly increased than normal and showed lower expression of potassium channels. However, cells co-cultured with MSC showed decreased proliferation capability and down-regulated expression of ion channel of PAMSCs. The protein array data showed that the changes of PAMSCs was substantially associated with a high level of tumor necrosis factor alpha (TNFα) secretion from MSC. We further demonstrated that TNFα rescued the cell behavior of PAMSCs through activating the expression of P53 and NF-kB and inducing cell cycle arrest by P21/CDK2/CDK4 downregulation. These findings suggested that MSCs could attenuate abnormal function of PAMSCs by TNFα secretion, which was more or less associated with the beneficial effects of MSC on improving PAH.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mesenchymal stem cells; Pulmonary arterial hypertension; Pulmonary artery smooth muscle cells; TNFα; Vascular remodeling

Year:  2020        PMID: 32878707     DOI: 10.1016/j.bbrc.2020.08.064

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Changes of serum levels of tumor necrosis factor (TNF-α) and soluble interleukin-2 receptor (SIL 2R) in patients with cervical cancer and their clinical significance.

Authors:  Jing Sha; Jing Du; Jianhong Yang; Xueliang Hu; Li Li
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Potential biomarkers and therapeutic targets of idiopathic pulmonary arterial hypertension.

Authors:  Wenjun He; Xi Su; Lingdan Chen; Chunli Liu; Wenju Lu; Tao Wang; Jian Wang
Journal:  Physiol Rep       Date:  2022-01

Review 3.  Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Jaylen Hudson; Laszlo Farkas
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.